Figure 4
From: Efficacy of SPI-1865, a novel gamma-secretase modulator, in multiple rodent models
SPI-1865 dose-responsively lowers β-amyloid (Aβ) 42 and Aβ 38 after multiple oral doses. Sprague Dawley rats were orally administered SPI-1865 for six days, once a day (QD){AU query: ok as defined? yes} at a dose of 10, 30 or 60 mg/kg. Plasma and brain were harvested 24 hrs post the final dose and analyzed for compound, Aβ38, Aβ40, and Aβ42 levels. Data are graphed as a percent of vehicle control. *P-value < 0.01 based on analysis of variance (Dunnett's test).